Updated on 28 October 2025
Advancing Personalized Medicine Through Integrative Research and Clinical Excellence
Research Manager at Universidade de Coimbra - Faculdade de Coimbra
Coimbra, Portugal
About
The Faculty of Medicine of the University of Coimbra (FMUC), in partnership with the Coimbra Institute for Clinical and Biomedical Research (iCBR) and Unidade Local de Saúde de Coimbra (ULSC), offers a unique translational research ecosystem bridging cutting-edge science with direct clinical application.
Our integrated research infrastructure spans genomic and epigenetic tumor characterization, liquid biopsy technologies, and predictive modeling for disease progression and patient stratification. We specialize in identifying novel biomarkers for diagnosis and prognosis, developing therapeutic targets, and establishing primary tumor cell cultures with comprehensive cytogenomic profiling.
Through our direct connection to ULSC—a major healthcare provider serving a broad patient population—we ensure seamless translation of research findings into clinical practice. This partnership enables access to diverse patient cohorts, real-world clinical data, and validation of personalized medicine approaches across multiple oncological and chronic disease pathologies.
Key expertise: Tumor genomics • Circulating tumor DNA • Predictive modeling • Biomarker discovery • Digital health • Clinical validation • Patient stratification • Community engagement
Field
- Receiver institution with a need to adopt a PM approach
- Screening & early detection programs (risk stratification, predictive tools)
- Personalised treatment pathways (tailored therapies, precision dosing)
- Patient management systems (decision-support tools, clinical workflows)
- Recovery & follow-up support systems (digital monitoring, apps, telemedicine)
- Data integration & interoperability solutions (EHRs, registries, data platforms)
- Tools for secure data sharing & secondary use (pseudonymisation, FAIR data)
- Clinical decision support systems for personalised medicine
- Standardisation & evaluation methodologies (protocols, metrics, QA/QC processes)
- Adaptation of care pathways for PM (embedding new tests/therapies into routine care)
- Cultural/organisational change approaches (staff training, workflow redesign)
- Patient engagement & empowerment strategies (self-management tools, shared decision-making)
- Initiating implementation of a PM solution (pilot site setup, proof-of-concept in clinical practice)
- Adaptation of an existing PM solution to local context (language, IT environment, regulations)
- Partial adoption of a PM solution (testing selected modules/components)
- Diagnostic tools (biomarkers, genetic tests, companion diagnostics)
- Theranostics (combined diagnostic + therapeutic approaches)
Organisation
Similar opportunities
Partnership
Investigate immuno-landscape in adenocarcinoma of the gastroesophageal junction (AEG)
- Company/SME
- Research organisation
- Hospital/medical centre
- Donor institution with a ready PM approach
Gerd Jomrich
PI at Medical University of Vienna (MUV, Upper-GI Research Group at the Dept. of General Surgery
Vienna, Austria
Expertise
- Receiver institution with a need to adopt a PM approach
- Clinical decision support systems for personalised medicine
- Personalised treatment pathways (tailored therapies, precision dosing)
- Patient management systems (decision-support tools, clinical workflows)
- Partial adoption of a PM solution (testing selected modules/components)
- Recovery & follow-up support systems (digital monitoring, apps, telemedicine)
- Initiating implementation of a PM solution (pilot site setup, proof-of-concept in clinical practice)
Juan Sebastián Suárez Valencia
COO at Health Force GmbH.
Vienna, Austria
Expertise
Offering expertise of the group of Prof. Markus Scholz
- Clinical decision support systems for personalised medicine
- Diagnostic tools (biomarkers, genetic tests, companion diagnostics)
- Personalised treatment pathways (tailored therapies, precision dosing)
- Partial adoption of a PM solution (testing selected modules/components)
- Screening & early detection programs (risk stratification, predictive tools)
Peter Ahnert
Senior Scientist at Leipzig University - Medical Faculty - IMISE
Leipzig, Germany